Who’s Hired? Sandoz Freshens Up Directors Board After Pivotal Year
As Lantheus Appoints Pharma Veteran As New CEO And Mallinckrodt Adds To Board
Sandoz nominated a new director candidate ahead of its annual meeting and Lantheus welcomed a familiar face as the new CEO. Meanwhile, Mallinckrodt strengthened its board with four new directors and Hikma announced another appointment this year.
You may also be interested in...
Despite denying any wrongdoing, Hikma joins a group of companies that have agreed to pay big settlements for their alleged respective roles in the ongoing opioid epidemic in the US.
Sandoz is rolling out its Tyruko natalizumab biosimilar rival to Biogen’s Tysabri in Germany, heralding the product as the “first and only biosimilar for multiple sclerosis.”
Sandoz has truly spread its wings since separating from Novartis, striking its first post-spinoff acquisition agreement by taking the Lucentis biosimilar Cimerli from Coherus BioSciences, which is moving in a different strategic direction.